title: The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept.
authors.forename: Mariusz
authors.initials: M
authors.lastname: Mogielnicki
authors.affiliation: First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland. d.swieczkowski@gumed.edu.pl.
authors.forename: Damian
authors.initials: D
authors.lastname: Swieczkowski
authors.forename: Witold
authors.initials: W
authors.lastname: Bachorski
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Zuk
authors.forename: Natasza
authors.initials: N
authors.lastname: Gilis-Malinowska
authors.forename: Aleksander
authors.initials: A
authors.lastname: Zarzeka
authors.forename: Piotr
authors.initials: P
authors.lastname: Merks
authors.forename: Marcin
authors.initials: M
authors.lastname: Gruchala
authors.forename: Milosz
authors.initials: M
authors.lastname: Jaguszewski
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy*; D017277:Drug Approval / Q000458:organization & administration*; D005060:Europe; D006801:Humans; D019338:Polypharmacy; D014481:United States; D014486:United States Food and Drug Administration